Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210009 | 0.81 | PIK3CA (0.33) | PLAULOXL2PIK3CALOX | |
| Hydrochloric Acid SCHEMBL8351731 | 0.80 | HRH1 (0.49) | PLAULOXL2TAAR1NOTUMASIC3 | |
| SCHEMBL3711754 | 0.80 | PLAU (0.47) | PLAUNOTUMSREBF2PIK3CAFDPS | |
| SCHEMBL8257156 | 0.80 | SREBF2 (0.48) | PLAUNOTUMSREBF2PIK3CAFDPS | |
| SCHEMBL7387315 | 0.80 | PLAU (0.43) | PLAUNOTUMASIC3SREBF2PIK3CA | |
| SCHEMBL29935002 | 0.80 | PLAU (0.47) | PLAUNOTUMSREBF2PIK3CAFDPS | |
| SCHEMBL2125037 | 0.79 | PRMT5 (0.46) | LOXL2ASIC3PIK3CAHRH1 | |
| Iodide SCHEMBL21332483 | 0.78 | PLAU (0.42) | PLAUNOTUMASIC3SREBF2PIK3CA | |
| Hydrochloric Acid SCHEMBL9413204 | 0.78 | PLAU (0.42) | PLAUNOTUMASIC3SREBF2PIK3CA | |
| SCHEMBL9116683 | 0.77 | NOTUM (0.56) | TAAR1NOTUMASIC3HRH1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158799-B2 | Hydroxyquinoline derivatives | Merck Patent Gesellschaft MIT Meschraenkter Haftung (DE) | 2012-04-17 | — | — | US | disclosed |
| US-20080312278-A1 | Hydroxyquinoline Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | disclosed |
| WO-2008085008-A1 | T-CELL INHIBITING COMPOUNDS AND THEIR USE FOR THE TREATMENT OF T-CELL-MEDIATED DISEASES | MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE (KR) | 2008-07-17 | — | — | WO | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20030187033-A1 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-0189678-B1 | ELECTROCHEMICAL REDUCTIONS OF PYRIDINE CARBOXAMIDE BASES | REILLY INDUSTRIES, INC. (US) | 1991-11-06 | — | — | EP | disclosed |
| EP-0161737-B1 | ELECTROCHEMICAL REDUCTIONS OF CYANOPYRIDINE BASES | REILLY INDUSTRIES, INC. (US) | 1991-06-05 | — | — | EP | disclosed |
| EP-0237908-B1 | PYRIDINE DERIVATIVES | MERCK PATENT GmbH (DE) | 1990-08-29 | — | — | EP | disclosed |
| US-4906642-A | Pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-03-06 | — | — | US | disclosed |
| EP-0237908-A2 | Pyridine derivatives | MERCK PATENT GmbH (DE) | 1987-09-23 | — | — | EP | disclosed |
| US-4695352-A | Electrochemical reduction of pyridine carboxamide bases | REILLY TAR & CHEMICAL CORPORATION (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0189678-A1 | Electrochemical reductions of pyridine carboxamide bases | REILLY INDUSTRIES, INC. (US) | 1986-08-06 | — | — | EP | disclosed |
| EP-0161737-A1 | Electrochemical reductions of cyanopyridine bases | REILLY INDUSTRIES, INC. (US) | 1985-11-21 | — | — | EP | disclosed |
| US-4482437-A | Electrochemical reductions of cyanopyridine bases | REILLY TAR & CHEMICAL CORP. (US) | 1984-11-13 | — | — | US | disclosed |
| US-4112100-A | INCREASING THE ENDOGENOUS PRODUCTION OF PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4069224-A | N-(PYRIDYLALKYL)BENZAMIDES, IMPROVE PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-01-17 | — | — | US | disclosed |
| US-4008326-A | INCREASING PRODUCTION OF PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312278-A1 | Hydroxyquinoline Derivatives | MKI67, CCNT1, CCNY | PLAU 4774/4885LOXL2 2132/4885TAAR1 2253/4885 |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | KCNH1, KCNH2, KCNJ2 | PLAU 3960/4885LOXL2 4392/4885TAAR1 1313/4885 |
| US-20030187033-A1 | Anthranilamides and methods of their use | KCNH1, KCNJ2, KCNH2 | PLAU 4303/4885LOXL2 4412/4885TAAR1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.